R347C Polymorphisms in ADRA1A Genes and Mirtazapine Treatment Response in Koreans with Major Depression
Journal of the Korean Society of Biological Psychiatry
; : 179-186, 2015.
Article
in Ko
| WPRIM
| ID: wpr-725352
Responsible library:
WPRO
ABSTRACT
OBJECTIVES:
Adrenergic alpha 1 and 2 receptors work as pathways to control the serotonergic neuron moderation and mirtazapine acts as antagonist of these receptors. The adrenoreceptor alpha 1a (ADRA1A) gene, which encodes adrenergic alpha 1 receptor, has Arg347Cys genetic polymorphism and the polymorphism has strong relationship with many neuro-psychiatric diseases. In this study, we explored the relationship between ADRA1A R347C polymorphism and mirtazapine treatment response in Koreans with major depression.METHODS:
352 patients enrolled in this study, and the symptoms were evaluated by 17-item Hamilton Depression Rating (HAMD-17) scale. After 1, 2, 4, 8, and 12 weeks of mirtazapine treatment, the association between ADRA1A R347C polymorphism and remission/response outcomes was evaluated.RESULTS:
Treatment response to mirtazapine was significantly better in T allele carriers than C allele homozygotes after 12 weeks of mirtazapine monotherapy. The percentile decline of HAMD-17 score in T allele carriers was larger than that of C allele homozygotes. ADRA1A R347C genotypes were not significantly associated with remission.CONCLUSIONS:
The result showed that treatment response to mirtazapine was significantly associated with ADRA1A R347C genetic polymorphism. T allele carriers showed better treatment response than C allele homozygotes. It can be supposed that T allele carriers have a trend of better treatment response to mirtazapine monotherapy.Key words
Full text:
1
Index:
WPRIM
Main subject:
Polymorphism, Genetic
/
Depression
/
Depressive Disorder, Major
/
Alleles
/
Serotonergic Neurons
/
Genotype
/
Homozygote
Limits:
Humans
Language:
Ko
Journal:
Journal of the Korean Society of Biological Psychiatry
Year:
2015
Type:
Article